Adaptimmune Archives - DelveInsight

Adaptimmune

transthyretin amyloidosis
Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manif...

Axovant rely on new gene therapy, Rise in Shares Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Fo...


transthyretin amyloidosis
Notizia

Arbor Biotechnologies shining with new CRISPR enzyme Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has r...


Editor's Pick
Top Drugs To Watch in HIV (2025)

Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...

An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.